Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • Publications
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • Publications
  • In the News

Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI)

Mar 27, 2013

Results of Lymphoseek® Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology

Mar 21, 2013

Navidea Biopharmaceuticals to Hold Conference Call to Discuss Lymphoseek FDA Approval

Mar 13, 2013

FDA Approves Navidea’s Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Use in Lymphatic Mapping

Mar 13, 2013

Navidea Announces Fourth Quarter and Full-Year 2012 Results

Mar 6, 2013

Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2012 Financial Results on Wednesday, March 6, 2013

Mar 4, 2013

Navidea Biopharmaceuticals to Present at the Cowen & Company 33rd Annual Health Care Conference

Feb 28, 2013

Navidea Biopharmaceuticals to Present at the Citi 2013 Global Healthcare Conference

Feb 19, 2013

Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Upcoming Scientific Meetings

Feb 7, 2013

Navidea Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference

Feb 6, 2013
    • 1...
    • 32
    • 33
    • 34
    • 35
    • 36
    • 37
    • 38
    • 39
    • 40
    • 41
    • ...43
    © 2023 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    linkedin
    Privacy Policy Disclaimer Sitemap